

AUG 19 2002

K022010  
page 1 of 2

**Summary of Safety and Effectiveness  
Smith & Nephew, Inc.  
Total Knee Femoral Component**

**Contact Person and Address**

Kim Kelly  
Project Manager, Clinical and Regulatory Affairs  
Smith & Nephew, Inc.  
Orthopaedic Division  
1450 East Brooks Road  
Memphis, TN 38116  
(901) 399-6566

**Device Description**

The **Total Knee Femoral Components** are designed for use with tibial and patellar components of the Genesis II or Profix Total Knee Systems. The **Total Knee Femoral Components** are metal alloy devices processed via a proprietary oxidation process.

**Device Classification Name**

21 CFR 888.3560 Knee joint patellofemorotibial metal/polymer/metal semi-constrained cemented prosthesis - Class II

**Indications for Use**

The Total Knee Femoral Components are indicated for rheumatoid arthritis; post-traumatic arthritis; degenerative arthritis; failed osteotomies; hemiarthroplasties, unicompartmental replacement; or total knee arthroplasties. The Total Knee Femoral Components are single use only and are intended for implantation with bone cement.

**Mechanical and Clinical Data**

A review of the mechanical test data indicated that the **Total Knee Femoral Components** are equivalent to devices currently used clinically and are capable of withstanding expected *in vivo* loading without failure.

**Wear Claims**

The following marketing claim will be made for the **Total Knee Femoral Components**:

“ {Total Knee Femoral Components} offer an 85% reduction in aggregate wear rate as compared to cobalt chrome (CoCr) femoral components ( $0.69 \pm 0.52$  mm<sup>3</sup>/million cycles vs.  $4.68 \pm 2.30$  mm<sup>3</sup>/million cycles). Testing was performed in a multi-axial knee joint simulator for a minimum of 6 million cycles per individual test using size 5 Genesis II femoral components as an articulating counterface, size 5 Genesis II UHMWPE tibial inserts, and Hyclone bovine calf serum as a lubricant. UHMWPE tibial inserts were sterilized via ethylene oxide. For each test condition the aggregate wear rates were computed as the slope of the line fit through the averaged data (n=3) after the initial

K00010  
page 2 of 2

wear-in period of 1.94 million cycles (i.e., 1.94 – 6.13 million cycles). The results of in-vitro tests have not been shown to correlate with clinical wear mechanisms.”

### **Substantial Equivalence Information**

The substantial equivalence of the **Total Knee Femoral Components** is substantiated by its similarities in design features, overall indications, and material composition as existing components of the Genesis II and Profix Total Knee Systems distributed by Smith & Nephew, Inc.



AUG 19 2002

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Ms. Kim P. Kelly, M.S.  
Project Manager, Clinical and Regulatory Affairs  
Smith & Nephew, Inc.  
Orthopaedic Division  
1450 East Brooks Road  
Memphis, Tennessee 38116

Re: K022010  
Trade/Device Name: Total Knee Femoral Components  
Regulation Number: 21 CFR 888.3560  
Regulation Name: Knee joint patellofemorotibial polymer/metal/polymer semi-constrained  
cemented prosthesis  
Regulatory Class: II  
Product Code: JWH  
Dated: July 22, 2002  
Received: July 23, 20002

Dear Ms. Kelly:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "Celia M. Witten", with a long horizontal flourish extending to the right.


Celia M. Witten, Ph.D., M.D.  
Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

K022010  
page 1 of 1

## Total Knee Femoral Components Indications Statement

The Total Knee Femoral Components are indicated for rheumatoid arthritis; post-traumatic arthritis; degenerative arthritis; and failed osteotomies, hemiarthroplasties; or total knee arthroplasties. The Total Knee Femoral Components are single use only and are intended for implantation with bone cement.



(Division Sign-Off)  
Division of General, Restorative  
and Neurological Devices

510(k) Number \_\_\_\_\_

K022010

---

Concurrence of CDRH, Office of Device Evaluation

Prescription Use \_\_\_\_\_

OR  
(Per 21 CFR 801.109)

Over-The Counter Use \_\_\_\_\_